19 research outputs found

    [Grußwort zur Eröffnung der Tagung: 6th Frankfurt Scientific Symposium, GNARP und wie sie die Welt sieht: Aussichten transatlantischer Partnerschaft im digitalen Zeitalter: 5.10.2006 - 7.10.2006]

    Get PDF
    ... This year's Scientific Symposium of the University Library is already number six in the row. It was again prepared and organised like some of the previous conferences together with our North American partners. This means that a continuous specialists’ discussion and a professional partnership have been already installed. All librarians and information managers are invited to learn more about the results of this co­operation every year when it's time for the next Symposium during Frankfurt Book Fair. ..

    IFLA '97 - ein Kurzbericht

    Get PDF

    QRICH1 variants in Ververi‐Brady syndrome—delineation of the genotypic and phenotypic spectrum

    Get PDF
    Abstract Ververi‐Brady syndrome (VBS, # 617982) is a rare developmental disorder, and loss‐of‐function variants in QRICH1 were implicated in its etiology. Furthermore, a recognizable phenotype was proposed comprising delayed speech, learning difficulties and dysmorphic signs. Here, we present four unrelated individuals with one known nonsense variant (c.1954C > T; p.[Arg652*]) and three novel de novo QRICH1 variants, respectively. These included two frameshift mutations (c.832_833del; p.(Ser278Leufs*25), c.1812_1813delTG; p.(Glu605Glyfs*25)) and interestingly one missense mutation (c.2207G > A; p.[Ser736Asn]), expanding the mutational spectrum. Enlargement of the cohort by these four individuals contributes to the delineation of the VBS phenotype and suggests expressive speech delay, moderate motor delay, learning difficulties/mild ID, mild microcephaly, short stature and notable social behavior deficits as clinical hallmarks. In addition, one patient presented with nephroblastoma. The possible involvement of QRICH1 in pediatric cancer assumes careful surveillance a key priority for outcome of these patients. Further research and enlargement of cohorts are warranted to learn about the genetic architecture and the phenotypic spectrum in more detail

    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    Get PDF
    Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

    BSKW: Sprach- und Kulturwissenschaften erhalten eine eigene Bibliothek : das Konzept von sechs Bereichsbibliotheken an der Goethe-Universität ist vollendet

    No full text
    Ein großer Moment für die Entwicklung des Campus Westend: Am 28. September wurde in Anwesenheit des hessischen Finanzministers Michael Boddenberg, der Staatssekretärin des Ministeriums für Wissenschaft und Kunst Ayse Asar und Universitätspräsident Prof. Enrico Schleiff das neue Gebäude SKW feierlich eingeweiht. Auch für die Universitätsbibliothek (UB JCS) ein großer Schritt, denn somit ist das bereits vor 20 Jahren vom damaligen Bibliotheksdirektor Berndt Dugall und Universitätspräsident Prof. Rudolf Steinberg geschmiedete Konzept von sechs Bereichsbibliotheken und einer Zentralbibliothek in Bezug auf die Bereichsbibliotheken vollendet. Diese neue sechste Bereichsbibliothek der UB JCS betreut die Fachgebiete der Sprach- und Kulturwissenschaften. Dafür stand nicht nur ein aufwendiger Umzug vom Campus Bockenheim zum Campus Westend an, sondern zugleich auch eine Zusammenführung von insgesamt zwölf Teilbibliotheken. Der UniReport konnte mit der stellvertretenden Direktorin der Universitätsbibliothek, Dr. Angela Hausinger, und der kommissarischen Leitung der BSKW, Christiane Schaper (zugleich Leitung BzG), über die Bedeutung der neuen BSKW sprechen
    corecore